Products
Palverafusp Biosimilar Fusion Protein (VEGF-A) for Research
Cat No.: GMP-Bios-INN-1325
Anti-VEGF therapeutic antibody (Pre-made Palverafusp biosimilar,Fusion Protein) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Palverafusp (development code IMM-2510) is a fusion protein developed by ImmuneOnco Biopharma for solid tumors. It is in Phase I/II clinical development. The molecule combines antibody and cytokine domains for targeted immune activation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1325-1mg | 1mg | 3090 |
| GMP-Bios-INN-1325-10mg | 10mg | |
| GMP-Bios-INN-1325-100mg | 100mg | |
| GMP-Bios-INN-1325-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Palverafusp biosimilar, Fusion Protein targeting VEGF: Recombinant therapeutic protein targeting VEGFA/Vascular endothelial growth factor A/long form/L-VEGF |
| INN Name | Palverafusp |
| Target | VEGF |
| Format | Fusion Protein |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | 5x8l:FK:HM:GL:JO:SN |
| 99% SI Structure | 5xxy:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | ImmuneOnco Biopharma |
| Conditions Approved | na |
| Conditions Active | Solid tumours |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
